Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. BGI Genomics Co., Ltd.
  6. Summary
    300676   CNE100003449

BGI GENOMICS CO., LTD.

(300676)
  Report
End-of-day quote Shenzhen Stock Exchange  -  2022-06-30
70.91 CNY   -1.10%
06/28BGI Genomics Announces Final Profit Distribution for 2021 payable on 06 July 2022
CI
05/19BGI Genomics Co., Ltd. Approves Cash Dividend for the Year 2021
CI
05/12Exclusive-Biden eyes new ways to bar China from scooping up U.S. data
RE
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shenzhen Stock Exchange
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
69.09 69.25 69.97 71.7 70.91 Last
5220657 4283533 7920147 6221230 3824632 Volume
+1.44% +0.23% +1.04% +2.47% -1.10% Change
Estimated financial data (e)
Sales 2022 5 834 M 871 M 871 M
Net income 2022 1 035 M 154 M 154 M
Net Debt 2022 - - -
P/E ratio 2022 23,8x
Yield 2022 -
Sales 2023 5 782 M 863 M 863 M
Net income 2023 1 099 M 164 M 164 M
Net Debt 2023 - - -
P/E ratio 2023 25,0x
Yield 2023 -
Capitalization 29 067 M 4 338 M 4 338 M
Capi. / Sales 2022 4,98x
Capi. / Sales 2023 5,03x
Nbr of Employees -
Free-Float 52,2%
More Financials
Company
BGI Genomics Co. is a leading provider of genomic and proteomic sequencing services primarily to academic institutions, pharmaceutical companies and healthcare providers. The company also provides genomic solutions for biomarker research and development, screening for some of the trisomies present at birth (trisomy 21, trisomy 18 and trisomy 13) and solutions for neo-antigen identification for immuno-oncology... 
Read more
More about the company
Ratings of BGI Genomics Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about BGI GENOMICS CO., LTD.
06/28BGI Genomics Announces Final Profit Distribution for 2021 payable on 06 July 2022
CI
05/19BGI Genomics Co., Ltd. Approves Cash Dividend for the Year 2021
CI
05/12Exclusive-Biden eyes new ways to bar China from scooping up U.S. data
RE
05/09BGI Genomics Develops Hepatitis Test Kits For Children
MT
05/06Illumina ordered to pay BGI subsidiary $333 million in DNA-sequencing patent case
RE
04/25BGI Genomics Co., Ltd. Announces Final Cash Dividend Proposal for 2021
CI
04/22BGI Genomics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2..
CI
03/25New World Development Company Limited - Share for Good Receives Support from All Corner..
AQ
03/12China approves five COVID-19 antigen kits for self-testing - CCTV
RE
02/25BGI Genomics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 20..
CI
01/25BGI Genomics Co., Ltd. announces an Increase in Equity Buyback.
CI
01/09BGI Genomics Wins Nod to Sell Cancer Tests Kits in Saudi Arabia; Shares Jump 3%
MT
01/05Tranche Update on BGI Genomics Co., Ltd.'s Equity Buyback Plan announced on October 29,..
CI
2021BGI Genomics Co., Ltd. agreed to acquire 11% stake in Shenzhen Zaozhidao Technology CO...
CI
2021Monkey-brain study with link to China's military roils top European university
RE
More news
News in other languages on BGI GENOMICS CO., LTD.
06/28BGI Genomics annonce la distribution finale des bénéfices pour 2021 payable le 06 juill..
05/19BGI Genomics Co., Ltd. approuve le dividende en espèces pour l'année 2021
05/12Exclusif - Biden envisage de nouveaux moyens d'empêcher la Chine de s'emparer des donné..
05/09BGI Genomics développe des kits de test de l'hépatite pour les enfants
05/06Illumina condamnée à payer 333 millions de dollars à une société chinoise dans une affa..
More news
Analysis
Illumina ordered to pay BGI subsidiary $333 million in DNA-sequencing patent case
Chart BGI GENOMICS CO., LTD.
Duration : Period :
BGI Genomics Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BGI GENOMICS CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 70,91
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Ye Yin General Manager & Director
Jian Wang Chairman
Song Gang Li Chairman-Supervisory Board
Ai Min Xu Independent Director
Yu Hui Wu Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BGI GENOMICS CO., LTD.-19.24%4 338
EXACT SCIENCES CORPORATION-47.15%7 237
GUARDANT HEALTH, INC.-56.35%4 450
IOVANCE BIOTHERAPEUTICS, INC.-39.92%1 803
BEIJING STRONG BIOTECHNOLOGIES, INC.-12.36%1 527
VERACYTE, INC.-48.79%1 507